Updated Evidence to Support the Emergency Use of COVID-19 Convalescent Plasma | NLM

Disaster Information Management Research Center | NLM

Updated Evidence to Support the Emergency Use of COVID-19 Convalescent Plasma

09/23/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 9/23/2020. This five-page document describes four lines of evidence that continue to support the emergency use of COVID-19 Convalescent Plasma at this time, one month after initial issuance of the Emergency Use Authorization: 1) historical data regarding prior experience with the use of convalescent plasma in other outbreak settings; 2) data from animal studies; 3) data that continues to emerge in the published literature from clinical studies performed during the current outbreak; and 4) results obtained from a large expanded access treatment protocol (National Expanded Program). (PDF)